245 related articles for article (PubMed ID: 30044395)
41. Identifying the correlation between drug/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology.
George M; Ghosh I
Eur J Pharm Sci; 2013 Jan; 48(1-2):142-52. PubMed ID: 23085547
[TBL] [Abstract][Full Text] [Related]
42. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods.
Peltonen L; Hirvonen J
J Pharm Pharmacol; 2010 Nov; 62(11):1569-79. PubMed ID: 21039542
[TBL] [Abstract][Full Text] [Related]
43. Analysis of heat generation during the production of drug nanosuspensions in a wet stirred media mill.
Guner G; Seetharaman N; Elashri S; Mehaj M; Bilgili E
Int J Pharm; 2022 Aug; 624():122020. PubMed ID: 35842083
[TBL] [Abstract][Full Text] [Related]
44. Review of nanosuspension formulation and process analysis in wet media milling using microhydrodynamic model and emerging characterization methods.
Tian Y; Wang S; Yu Y; Sun W; Fan R; Shi J; Gu W; Wang Z; Zhang H; Zheng A
Int J Pharm; 2022 Jul; 623():121862. PubMed ID: 35671851
[TBL] [Abstract][Full Text] [Related]
45. Development of nanostructured lipid carriers containing salicyclic acid for dermal use based on the Quality by Design method.
Kovács A; Berkó S; Csányi E; Csóka I
Eur J Pharm Sci; 2017 Mar; 99():246-257. PubMed ID: 28012940
[TBL] [Abstract][Full Text] [Related]
46. Roadmap for implementation of quality by design (QbD) for biotechnology products.
Rathore AS
Trends Biotechnol; 2009 Sep; 27(9):546-53. PubMed ID: 19647883
[TBL] [Abstract][Full Text] [Related]
47. Toward biotherapeutic product real-time quality monitoring.
Guerra A; von Stosch M; Glassey J
Crit Rev Biotechnol; 2019 May; 39(3):289-305. PubMed ID: 30724608
[TBL] [Abstract][Full Text] [Related]
48. Double Optimization of Rivastigmine-Loaded Nanostructured Lipid Carriers (NLC) for Nose-to-Brain Delivery Using the Quality by Design (QbD) Approach: Formulation Variables and Instrumental Parameters.
Cunha S; Costa CP; Loureiro JA; Alves J; Peixoto AF; Forbes B; Sousa Lobo JM; Silva AC
Pharmaceutics; 2020 Jun; 12(7):. PubMed ID: 32605177
[TBL] [Abstract][Full Text] [Related]
49. Risk management and statistical multivariate analysis approach for design and optimization of satranidazole nanoparticles.
Dhat S; Pund S; Kokare C; Sharma P; Shrivastava B
Eur J Pharm Sci; 2017 Jan; 96():273-283. PubMed ID: 27693296
[TBL] [Abstract][Full Text] [Related]
50. Increase in Dissolution Rate of Zotepine via Nanomilling Process - Impact of Dried Nanocrystalline Suspensions on Bioavailability.
Parmar K; Oza K
AAPS PharmSciTech; 2021 Dec; 23(1):20. PubMed ID: 34907489
[TBL] [Abstract][Full Text] [Related]
51. A quality by design framework for developing nanocrystal bioenabling formulations.
Simões A; Castro RAE; Veiga F; Vitorino C
Int J Pharm; 2023 Nov; 646():123393. PubMed ID: 37717717
[TBL] [Abstract][Full Text] [Related]
52. Optimization of formulation and process parameters for the production of carvedilol nanosuspension by wet media milling.
Medarević D; Djuriš J; Ibrić S; Mitrić M; Kachrimanis K
Int J Pharm; 2018 Apr; 540(1-2):150-161. PubMed ID: 29438724
[TBL] [Abstract][Full Text] [Related]
53. Quality-by-Design Concepts to Improve Nanotechnology-Based Drug Development.
Rawal M; Singh A; Amiji MM
Pharm Res; 2019 Sep; 36(11):153. PubMed ID: 31482243
[TBL] [Abstract][Full Text] [Related]
54. A quality by design approach using artificial intelligence techniques to control the critical quality attributes of ramipril tablets manufactured by wet granulation.
Aksu B; Paradkar A; de Matas M; Özer Ö; Güneri T; York P
Pharm Dev Technol; 2013 Feb; 18(1):236-45. PubMed ID: 22881350
[TBL] [Abstract][Full Text] [Related]
55. Quality by design (QbD) approach for design and development of drug-device combination products: a case study on flunisolide nasal spray.
Chudiwal SS; Dehghan MHG
Pharm Dev Technol; 2018 Dec; 23(10):1077-1087. PubMed ID: 27616074
[TBL] [Abstract][Full Text] [Related]
56. Application of the Quality by Design Concept (QbD) in the Development of Hydrogel-Based Drug Delivery Systems.
Mohseni-Motlagh SF; Dolatabadi R; Baniassadi M; Baghani M
Polymers (Basel); 2023 Nov; 15(22):. PubMed ID: 38006131
[TBL] [Abstract][Full Text] [Related]
57. Quality-by-Design Approach to Process Intensification of Bioinspired Silica Synthesis.
Manning JRH; Brambila C; Rishi K; Beaucage G; Davies GL; Patwardhan SV
ACS Sustain Chem Eng; 2024 Mar; 12(12):4900-4911. PubMed ID: 38550969
[TBL] [Abstract][Full Text] [Related]
58. Design of experiments (DoE) in pharmaceutical development.
N Politis S; Colombo P; Colombo G; M Rekkas D
Drug Dev Ind Pharm; 2017 Jun; 43(6):889-901. PubMed ID: 28166428
[TBL] [Abstract][Full Text] [Related]
59. Impact of process parameters on the breakage kinetics of poorly water-soluble drugs during wet stirred media milling: a microhydrodynamic view.
Afolabi A; Akinlabi O; Bilgili E
Eur J Pharm Sci; 2014 Jan; 51():75-86. PubMed ID: 24036164
[TBL] [Abstract][Full Text] [Related]
60. Influence of Drug Brittleness, Nanomilling Time, and Freeze-Drying on the Crystallinity of Poorly Water-Soluble Drugs and Its Implications for Solubility Enhancement.
Colombo M; Orthmann S; Bellini M; Staufenbiel S; Bodmeier R
AAPS PharmSciTech; 2017 Oct; 18(7):2437-2445. PubMed ID: 28168626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
